Cargando…
Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients
BACKGROUND: This short-term study assessed the efficacy and safety of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients; here, we report a prespecified subgroup analysis of patients undergoing peritoneal dialysis. METHODS: Men and women (n = 39) who had received continuo...
Autores principales: | Hutchison, Alastair J, Gill, Maggie, Copley, J Brian, Poole, Lynne, Wilson, Rosamund J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582545/ https://www.ncbi.nlm.nih.gov/pubmed/23418668 http://dx.doi.org/10.1186/1471-2369-14-40 |
Ejemplares similares
-
Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate
por: Mohammed, Ismail A, et al.
Publicado: (2008) -
Lanthanum carbonate: safety data after 10 years
por: Hutchison, Alastair J, et al.
Publicado: (2016) -
Hyperphosphatemia and hs-CRP Initiate the Coronary Artery Calcification in Peritoneal Dialysis Patients
por: Shang, Da, et al.
Publicado: (2017) -
Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients
por: Imtiaz, Rameez, et al.
Publicado: (2017) -
Use of Nicotinamide to Treat Hyperphosphatemia in Dialysis Patients
por: Lenglet, Aurélie, et al.
Publicado: (2013)